ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells

Ricardo Parrondo(Jacksonville College), Carlos Perez‐Stable(University of Miami)

PeerJ

September 12, 2013

10.7717/peerj.144

Cited by 56

Related Papers

Betulinic Acid Selectively Increases Protein Degradation and Enhances Prostate Cancer-Specific Apoptosis: Possible Role for Inhibition of Deubiquitinase Activity

|PLoS ONE|2013|76

Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

|Clinical Cancer Research|2023|38

Inhibiting Multiple Deubiquitinases to Reduce Androgen Receptor Expression in Prostate Cancer Cells

|Scientific Reports|2018|25

Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting

|Cancers|2021|20

Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities

|Blood Cancer Journal|2024|8